Is There a Vaccine for Syphilis? The Current Status

No approved vaccine for syphilis exists, and none is currently in human clinical trials. Despite more than a century of effort since the bacterium that causes the disease was first isolated, researchers have not yet produced a formulation that fully prevents infection in laboratory animals, let alone in people. That said, the past several years have seen genuinely encouraging progress, particularly in laboratory cultivation of the bacterium and in early-stage vaccine candidates tested in rabbits. The gap between where the science stands today and a shot you could actually receive remains wide, but it is narrower than it has been at any point in the modern era.

Why a Syphilis Vaccine Matters More Than Ever

Syphilis rates have been climbing worldwide for over a decade, reversing decades of decline. The disease is curable with penicillin and preventable through screening and behavioral measures, yet those strategies have clearly not been enough to stop the resurgence. Disparities in access to testing, partner notification, and prenatal screening continue to undermine control efforts in many regions.¹ The rising numbers have prompted a renewed push for a vaccine, because a preventive tool would not depend on catching every case in time or on the cooperation of every sexual partner in a chain of transmission.

Mathematical modeling suggests that an effective vaccine could sharply reduce syphilis prevalence under a wide range of scenarios and would likely outperform even expanded “screen and treat” programs that rely on existing antibiotics.² That modeling work underscores a practical reality: treatment-based strategies alone have a ceiling, especially in populations where reinfection is common and access to care is uneven.

What Makes Syphilis So Hard to Vaccinate Against

The bacterium responsible for syphilis, Treponema pallidum, is an unusual pathogen. Its outer membrane is almost barren of the surface proteins that the immune system typically uses to recognize and attack bacteria. This sparse protein coat is the structural basis for the organism’s well-known ability to invade tissues, evade immune defenses, and persist in the body for years.³ If there are few targets on the bacterial surface for antibodies to latch onto, designing a vaccine that teaches the immune system to find and neutralize the organism becomes far more difficult than it is for bacteria with protein-rich outer membranes.

Adding to the challenge, T. pallidum could not be grown continuously in the laboratory until very recently. For over a hundred years, researchers had to maintain the organism by passing it through live rabbits, a slow and expensive process that limited the supply of bacteria available for study. Without a reliable culture system, basic experiments on the bacterium’s biology, its vulnerabilities, and its interactions with the immune system were extraordinarily hard to perform.

The Cultivation Breakthrough

In 2018, researchers reported the first successful long-term cultivation of T. pallidum outside an animal host. Using a modified culture medium and a system that co-incubated the spirochetes with rabbit epithelial cells under low-oxygen conditions, they achieved continuous growth for over six months, with the bacteria retaining full infectivity.⁴ The organism divides slowly even under ideal conditions, with a doubling time of roughly 33 to 45 hours, comparable to what happens during natural infection.⁵

This was a landmark moment. Having a laboratory culture system means researchers can now grow enough bacteria to study their proteins in detail, test potential vaccine antigens more efficiently, and eventually produce standardized material for vaccine manufacturing. Before 2018, the field was working with one hand tied behind its back. The cultivation system has not removed every obstacle, but it has opened experimental avenues that simply did not exist before.

Where Vaccine Candidates Stand in Animal Testing

Vaccine research against syphilis has historically relied on rabbits, which develop disease that closely resembles human syphilis. Published vaccine formulations based on a subset of the pathogen’s outer membrane proteins have so far conferred only partial protection in immunized rabbits.⁶ “Partial protection” means that vaccinated animals still get infected, but they develop less severe disease, carry lower bacterial loads, and show less spread of the infection to distant tissues. That is a meaningful result, but it falls short of the sterilizing immunity that would prevent infection altogether.

One of the more promising approaches involves a cocktail of three recombinant proteins: TprC, TprK, and Tp0751. In rabbits, immunization with this combination significantly reduced the development of syphilis sores, lowered the number of bacteria at challenge sites, and inhibited the spread of infection to other parts of the body.⁷ Separate work on TprC variants has confirmed that immunized rabbits develop attenuated primary sores, reduced bacterial burden at challenge sites, and limited dissemination to lymph nodes, with immune responses targeting surface-exposed regions across multiple related proteins in the Tpr family.⁸

Another protein under study, TprK, triggers both a strong cell-mediated immune response and the production of antibodies that help immune cells engulf and destroy the bacteria more effectively.⁹ Understanding exactly which arms of the immune system matter most for protection is one of the key pieces of the puzzle that researchers are still assembling.

mRNA Vaccines Enter the Picture

The success of mRNA vaccines against COVID-19 raised an obvious question: could the same technology work for syphilis? Early results in animal models are encouraging. An mRNA vaccine targeting the TP0954 protein, delivered in lipid nanoparticles, outperformed a traditional protein-based version of the same antigen in rabbits. Vaccinated animals showed greater reduction in sore development and lower bacterial loads both at the site of infection and in distant organs.¹⁰

A separate mRNA vaccine targeting a different protein, TP0435, showed similar advantages. In rabbits, the mRNA version completely prevented ulcer formation at the challenge sites and produced lower bacterial loads than the protein vaccine, while also limiting the spread of bacteria to other tissues.¹¹ The fact that two independent mRNA candidates targeting different antigens both outperformed their protein-based counterparts is notable. mRNA platforms can also be manufactured faster and scaled more easily than traditional recombinant protein vaccines, which could matter down the road when the field is ready to move toward human trials.

To be clear, even the best rabbit results so far represent partial protection, not complete prevention of infection. And rabbit immunity does not always translate directly to humans. But the consistency of the findings across multiple antigens and platforms gives the field more confidence that a workable vaccine is not an impossibility.

The Strain Diversity Problem

One complication that could affect how well any vaccine works in the real world is genetic diversity among circulating syphilis strains. Whole-genome sequencing of clinical samples from multiple countries has revealed two main strain lineages, with the SS14 lineage predominating globally. The older Nichols lineage is more genetically diverse and clusters into more distinct subgroups. Importantly, population-specific mutations have been found in some of the very outer membrane proteins that researchers are considering as vaccine targets.¹²

A study of early syphilis cases in Colombia found similar patterns: SS14-lineage strains predominated, and certain regions of key outer membrane proteins were highly variable among South American strains. Over half of all sequenced samples carried at least one mutation associated with resistance to macrolide antibiotics, a finding relevant to treatment but also a reminder that the bacterium is not genetically static.¹³

The practical concern is straightforward: if a vaccine is designed around proteins from one reference strain and the most common circulating strains carry different versions of those proteins, the vaccine might not work as well in the populations that need it most. Encouragingly, epitope-mapping studies have found that antibodies generated against one strain’s surface proteins tend to show some degree of cross-reactivity with variant sequences from other strains and even from related subspecies that cause yaws and bejel.¹⁴ That cross-reactivity is a hopeful sign, but the degree of real-world protection it would provide remains untested in humans.

Identifying the Right Targets

Because the outer membrane of T. pallidum has so few exposed proteins, finding the right ones to include in a vaccine is painstaking work. Researchers have turned to computational approaches, including reverse vaccinology, to identify candidate antigens. One study selected seven adhesin proteins, which help the bacterium attach to host cells, as potential vaccine targets and designed a multi-epitope vaccine construct in silico.¹⁵ These computational designs still need to be synthesized and tested in animals, but they represent a systematic way of searching the bacterium’s proteome for vulnerabilities.

One of those adhesins, TP0136, has been studied in more detail. Researchers screened the protein for specific immune-active regions and identified several spots that trigger both antibody and cell-mediated immune responses. They then tested these regions in rabbits that were immunized and subsequently infected, gathering data on how the immune system reacts to these particular fragments of the protein during active disease.¹⁶ This kind of fine-grained mapping is essential for figuring out which pieces of the bacterium to include in a vaccine and which would be red herrings.

What Still Needs to Happen Before Human Trials

The gap between promising rabbit data and a vaccine you can get at a clinic is substantial. Several critical needs have been identified by researchers in the field. The community of scientists working on T. pallidum is small relative to the scale of the problem, and funding has historically lagged behind what other sexually transmitted infections receive. A definitive understanding of the correlates of protection in humans, meaning which immune responses actually prevent or limit syphilis in people, does not yet exist. And there is no established industry partnership for syphilis vaccine production, the kind of commercial engagement that typically moves a candidate from the laboratory bench to a manufacturing plant.¹⁷

Diagnostics are another piece of the puzzle. Current blood tests for syphilis cannot distinguish between a recent infection, a past infection, and a previously treated infection.¹⁸ That limitation complicates clinical trial design. If you vaccinate someone, then expose them and test their blood, it can be hard to tell whether the vaccine prevented infection or the person’s immune system simply handled the infection quietly. Future trials will need either better diagnostic tools or creative study endpoints to get around this problem.

Doxycycline as a Stopgap

While waiting for a vaccine that may be years or decades away, a different prevention strategy has gained traction. Taking a dose of the antibiotic doxycycline within 72 hours after unprotected sex, a practice known as doxy-PEP (post-exposure prophylaxis), has shown striking reductions in bacterial sexually transmitted infections. In a major trial among men who have sex with men (MSM) and transgender women, the combined incidence of gonorrhea, chlamydia, and syphilis dropped by roughly two-thirds in the group taking doxycycline compared with standard care. Syphilis specifically was reduced by about 87% in participants on HIV pre-exposure prophylaxis.¹⁹

Real-world data from a public STI clinic in Philadelphia echoed these findings. Among people who opted for doxy-PEP during HIV prevention visits, the overall rate of any new STI dropped significantly, with a roughly 62% relative reduction while taking the antibiotic.²⁰ An Australian consensus statement has recommended considering doxy-PEP primarily for syphilis prevention in MSM at risk, while acknowledging disagreement among experts about whether the benefit of reducing other STIs outweighs the risk of driving antibiotic resistance.²¹

Doxy-PEP is not a substitute for a vaccine. It requires taking a pill after every potential exposure, works only against bacterial infections, and raises legitimate concerns about fostering antibiotic-resistant bacteria over time. But for high-risk populations right now, it represents the closest thing available to a preventive tool while vaccine research continues.

Would People Actually Get a Syphilis Vaccine?

Developing a vaccine is only half the battle. People have to be willing to take it, and STI vaccines carry social baggage that vaccines for flu or pneumonia do not. In a qualitative study of potential participants for future syphilis vaccine trials in the United States, the overwhelming majority, about 83%, said they would be interested in getting vaccinated if a syphilis vaccine were available. All participants described the idea as an important and helpful innovation. The small number who said no cited not being sexually active rather than concerns about the vaccine itself.²²

Broader surveys of public willingness to receive STI vaccines paint a more complicated picture. Stigma around sexually transmitted infections affects testing and treatment decisions, and researchers have flagged it as a likely factor in vaccine uptake as well. Some parents worry that vaccinating young people against STIs could encourage sexual activity, a concern that research on the HPV vaccine has consistently failed to support.²³ How a syphilis vaccine is framed and recommended, whether universally or only for high-risk groups, could significantly affect how widely it gets used. Experience with HPV vaccination suggests that universal recommendations reduce stigma and improve uptake compared with targeted approaches, a lesson that will likely inform how a future syphilis vaccine is rolled out.

Cross-Protection and Related Diseases

Syphilis is caused by one subspecies of Treponema pallidum, but closely related subspecies cause yaws and bejel, diseases that primarily affect the skin and bones in tropical regions. Early vaccine experiments found that immunizing rabbits against syphilis strains produced minimal protection against yaws strains, suggesting a degree of subspecies specificity.²⁴ More recent epitope-mapping work, however, has found that antibodies raised against syphilis proteins show various degrees of cross-reactivity with proteins from yaws and bejel strains.¹⁴

Whether that cross-reactivity would translate to meaningful cross-protection in people is unknown, but it raises an intriguing possibility. If a vaccine developed primarily for syphilis also offered some protection against yaws, it could have benefits well beyond the sexually transmitted infection context. The World Health Organization has an active campaign to eradicate yaws, and a cross-protective vaccine could accelerate that effort. For now, this remains speculative, but researchers designing syphilis vaccine antigens are paying attention to how their candidates interact with the immune responses triggered by related subspecies.